期刊文献+

卡铂3周联合紫杉醇每周给药治疗复发卵巢癌的疗效观察 被引量:1

下载PDF
导出
摘要 目的:本院主要针对卡铂3周联合紫杉醇每周给药治疗复发卵巢癌的疗效进行相应的临床研究。方法:主要针对2010-2012年到本院进行复发性卵巢癌治疗的50例患者进行相应的分组治疗,随机抽取其中的25例患者作为实验组,所进行的方法为卡铂3周联合紫杉醇每周给药治疗,将剩下的25例患者作为对照组,所进行的治疗方法为卡铂3周联合紫杉醇3周给药1次,在进行治疗一段时间以后,进行相应的效果评估。结果:经过一段时间的治疗,实验组疗效明显优于对照组,相应的不良反应也比对照组低。结论:运用卡铂3周联合紫杉醇每周给药治疗复发卵巢癌的疗效比较好,值得推广应用。
作者 黄丽娟
出处 《医学理论与实践》 2012年第24期3061-3062,共2页 The Journal of Medical Theory and Practice
  • 相关文献

参考文献4

  • 1Du Bois A, Liick HJ, Pfisterer J, et al. Second-line carboplatin and gemeitabine in platinum sensitive ovarian eancer-a dose- finding study by the arbeitsgemeinsehaft gyn:.kologisehe onkol- ogie (AGO) ovarian cancer study group[J]. Annals of Oneolo- gy, 2001,12 (8) ; 115-120.
  • 2Munetaka Takekurna, Makoto Maeda, Takachika Ozawa, et al. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer[J]. International Journal of Clinical Oncology, 2005,10(3) : 177-181.
  • 3Devansu Tewari, Bradley J. Monk, et al. Gemcitabine and cispl- atin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma[J]. Inves- tigational New Drugs, 2004,22 (4) : 475-478.
  • 4Pierluigi Benedetti Panici MD, Filippo Bellati MD, Natalina Manci MD, et al. Neoadjuvant chemotherapy followed by radi- cal surgery in patients affected by FIGO stage IVA cervical cancer[J] Annals of Surgical Oncology, 2007,14 (9): 2643- 2648.

同被引文献31

  • 1沈铿,李孟达,丰有吉,马丁,李子庭,谢辛,孔北华,崔恒,宋垒,彭芝兰,李力,吴鸣,陈亦乐,刘继红,吴令英,郎景和,中国妇科肿瘤学组.泰素周疗和三周疗法作为卵巢癌一线化疗的多中心对照研究[J].中华医学杂志,2005,85(30):2099-2103. 被引量:16
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
  • 3Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008[J]. IntJ Cancer, 2013, 132(5): 1133-1145.
  • 4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008, $8(2): 71-96.
  • 5Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 vl.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. [2016-03-28]. http://globocan. iarc.fr.
  • 6Thigpen T, Dubois A, McAlpine J, et aI. First-line therapy in ovarian cancer trials[J]. IntJ Gynecol Cancer, 2011, 21(4): 756- 762.
  • 7. Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer[J]. Nat Rev Clin Oncol, 2010, 7(10): 575-582.
  • 8Katsumata N, Yasuda M, Isonishi S,et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial[J]. Lancet Oncol, 2013, 14(10): 1020-1026.
  • 9Higgins Jp, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011 ]. The Cochrane Collaboration, 2011. http://www.cochrane- handbook.org.
  • 10Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15(4): 396- 405.

引证文献1

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部